Page last updated: 2024-11-04

isocitric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isocitric acid: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isocitric acid : A tricarboxylic acid that is propan-1-ol with a hydrogen at each of the 3 carbon positions replaced by a carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1198
CHEMBL ID539669
CHEBI ID30887
SCHEMBL ID8373
MeSH IDM0105608

Synonyms (37)

Synonym
nsc-203797
nsc203797
3-carboxy-2,3-dideoxypentaric acid
CHEBI:30887 ,
pentaric acid, 3-carboxy-2,3-dideoxy-
pentaric acid, 3-carboxy-2,3-dideoxy- (9ci)
1-hydroxy-1,2,3-propanetricarboxylic acid
isocitric acid (8ci)
3-carboxy-2,3-dideoxy-1-hydroxypropan-1,2,3-tricarboxylic acid
i-cit
isocitrate ,
C00311
isocitric acid
320-77-4
1-hydroxytricarballylic acid
1-hydroxypropane-1,2,3-tricarboxylic acid
dl-isocitric acid
91BDE4FE-7872-4F5E-B191-62956199D37C
CHEMBL539669
AKOS006227850
einecs 206-282-3
unii-9rw6g5d4mq
9rw6g5d4mq ,
bdbm92496
SCHEMBL8373
1-hydroxy-1,2,3-propanetricarboxylate
3-carboxy-2,3-dideoxy-pentaric acid
1-hydroxytricarballylate
threo-d(s)-iso-citrate
3-carboxy-2,3-dideoxy-pentarate
3-carboxy-2,3-dideoxy-1-hydroxypropan-1,2,3-tricarboxylate
DTXSID60861871
Q288927
FT-0775163
1-hydroxypropane-1,2,3-tricarboxylicacid
HY-113228
CS-0059363

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" At time of calving, nine ruminally cannulated Holstein cows were randomly assigned to ruminal dosing of 500 g/d tap water (CON, n = 4) or 500 g/d PG (PPG, n = 5)."( Effect of postpartum propylene glycol allocation to over-conditioned Holstein cows on concentrations of milk metabolites.
Bjerre-Harpøth, V; Larsen, M; Larsen, T; Storm, AC; Vestergaard, M, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tricarboxylic acidAn oxoacid containing three carboxy groups.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (34)

PathwayProteinsCompounds
Citric Acid Cycle2127
Congenital Lactic Acidosis2127
Fumarase Deficiency2127
Mitochondrial Complex II Deficiency2127
2-Ketoglutarate Dehydrogenase Complex Deficiency2127
Pyruvate Dehydrogenase Deficiency (E3)2127
Pyruvate Dehydrogenase Deficiency (E2)2127
Warburg Effect4652
Secondary Metabolites: Glyoxylate Cycle715
Glycolate and Glyoxylate Degradation II1221
The Oncogenic Action of 2-Hydroxyglutarate2734
The Oncogenic Action of Succinate2933
The Oncogenic Action of Fumarate2934
Glutaminolysis and Cancer3536
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Glutamine Metabolism2225
Citrate cycle ( Citrate cycle )2129
NAD+ + Isocitric acid = NADH + 2-Oxo-glutaric acid + CO2 ( Citrate cycle )35
Citric acid = Isocitric acid ( Citrate cycle )24
Amino acid metabolism pathway excerpt: histidine catabolism extension016
Citrate Cycle1930
Fluoroacetic acid toxicity05
TCA cycle, aerobic respiration020
Central carbon metabolism019
TCA cycle010
Primary carbon metabolism2330
Krebs cycle110
TCA cycle (Krebs cycle)3019
AtMetExpress overview0109
TCA cycle and deficiency of pyruvate dehydrogenase complex (PDHc)015
Metabolism overview078
Amino acid metabolism094
TCA cycle (aka Krebs or citric acid cycle)024

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Egl nine homolog 1Homo sapiens (human)IC50 (µMol)10,000.00000.00701.86148.0000AID721521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Methyl-accepting chemotaxis protein NahYPseudomonas putidaKd337.00008.50008.50008.5000AID1799787
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
response to hypoxiaEgl nine homolog 1Homo sapiens (human)
intracellular iron ion homeostasisEgl nine homolog 1Homo sapiens (human)
intracellular oxygen homeostasisEgl nine homolog 1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityEgl nine homolog 1Homo sapiens (human)
regulation of angiogenesisEgl nine homolog 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEgl nine homolog 1Homo sapiens (human)
negative regulation of cyclic-nucleotide phosphodiesterase activityEgl nine homolog 1Homo sapiens (human)
cardiac muscle tissue morphogenesisEgl nine homolog 1Homo sapiens (human)
heart trabecula formationEgl nine homolog 1Homo sapiens (human)
ventricular septum morphogenesisEgl nine homolog 1Homo sapiens (human)
labyrinthine layer developmentEgl nine homolog 1Homo sapiens (human)
response to nitric oxideEgl nine homolog 1Homo sapiens (human)
regulation of modification of postsynaptic structureEgl nine homolog 1Homo sapiens (human)
regulation protein catabolic process at postsynapseEgl nine homolog 1Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineEgl nine homolog 1Homo sapiens (human)
cellular response to hypoxiaEgl nine homolog 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingEgl nine homolog 1Homo sapiens (human)
ferrous iron bindingEgl nine homolog 1Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityEgl nine homolog 1Homo sapiens (human)
enzyme bindingEgl nine homolog 1Homo sapiens (human)
L-ascorbic acid bindingEgl nine homolog 1Homo sapiens (human)
peptidyl-proline dioxygenase activityEgl nine homolog 1Homo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activityEgl nine homolog 1Homo sapiens (human)
peptidyl-proline 4-dioxygenase activityEgl nine homolog 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmEgl nine homolog 1Homo sapiens (human)
cytosolEgl nine homolog 1Homo sapiens (human)
postsynaptic densityEgl nine homolog 1Homo sapiens (human)
intracellular membrane-bounded organelleEgl nine homolog 1Homo sapiens (human)
glutamatergic synapseEgl nine homolog 1Homo sapiens (human)
nucleusEgl nine homolog 1Homo sapiens (human)
cytoplasmEgl nine homolog 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1799787Isothermal Titration Calorimetry from Article 10.1074/jbc.M110.110403: \\Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: differential chemotactic response towards receptor ligands.\\2010The Journal of biological chemistry, Jul-23, Volume: 285, Issue:30
Identification of a chemoreceptor for tricarboxylic acid cycle intermediates: differential chemotactic response towards receptor ligands.
AID406767Inhibition of Bacillus licheniformis beta-lactamase BS3 in 25 mM acetate buffer at pH 52008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
2-Aminopropane-1,2,3-tricarboxylic acid: Synthesis and co-crystallization with the class A beta-lactamase BS3 of Bacillus licheniformis.
AID721529Displacement of 2OG from catalytic domain of PHD2 (181 to 426) (unknown origin) expressed in Escherichia coli at 400 uM2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.
AID721521Inhibition of PHD2 (unknown origin)2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.
AID420346Inhibition of Bacillus licheniformis BS3 beta-lactamase at pH 52009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.
AID721528Displacement of 2OG from FIH (unknown origin) expressed in Escherichia coli at 400 uM2013Journal of medicinal chemistry, Jan-24, Volume: 56, Issue:2
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.
AID406768Inhibition of beta-lactamase TEM1 in 25 mM acetate buffer at pH 52008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
2-Aminopropane-1,2,3-tricarboxylic acid: Synthesis and co-crystallization with the class A beta-lactamase BS3 of Bacillus licheniformis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (257)

TimeframeStudies, This Drug (%)All Drugs %
pre-199069 (26.85)18.7374
1990's46 (17.90)18.2507
2000's52 (20.23)29.6817
2010's58 (22.57)24.3611
2020's32 (12.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.88 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index102.82 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.37%)5.53%
Reviews11 (4.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.37%)0.25%
Other259 (95.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]